New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 28, 2014
05:35 EDTNSRGY, LRLCY, VRXNestle creates Nestle Skin Health with acquisition of Valeant assets for $1.4B
Nestlé (NSRGY) announced it would extend its activities to include the field of specialized medical skin treatments through the creation of Nestlé Skin Health S.A. The foundation for the company would be Galderma, the 50/50 joint venture with L'Oreal (LRLCY), which would become fully-owned by Nestlé. Bübchen, the company's existing infant skin care business would be merged into the new entity. The acquisition of Galderma is awaiting final regulatory clearance. Nestlé is announcing it will reinforce Nestlé Skin Health with the acquisition from the Canadian firm Valeant Pharmaceuticals (VRX) of the full rights to commercialize several key aesthetic dermatology products in the U.S. and Canada for $1.4B in cash. The two markets together represent more than half of the fast-growing medical aesthetics market around the world. Galderma already commercializes the products included in this transaction outside those markets. Nestlé is acquiring the full rights to commercialize in the U.S. and Canada Restylane, Perlane and Emervel, products used for corrective facial aesthetic treatments, and Dysport, an aesthetic dermatology treatment. It will also acquire the full rights to Sculptra, a unique treatment for aesthetic and medical uses in the U.S., Canada and many markets around the world.
News For NSRGY;VRX;LRLCY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 30, 2015
13:28 EDTLRLCYL'Oreal reports Q2 net profit EUR 1.77B, net EPS EUR 2.92
Reports Q2 sales up 3.6% EUR 6.38B. Reports Q2 Professional Products sales up 3.5% to EUR 887.7M. Reports Q2 Consumer Products sales up 2% to EUR 3.08B. Reports Q2 L'Oreal Luxe sales up 5.8% to EUR 1.73B. Reports Q2 Active Cosmetics sales up 6.5% to EUR 459.4M. Repots Q2 Total Cosmetics Divisions sales up 3.6% to EUR 6.16B.
July 27, 2015
08:42 EDTVRXValeant price target raised to $300 form $260 at Susquehanna
Subscribe for More Information
07:50 EDTVRXValeant price target raised to $284 from $235 at Morgan Stanley
Morgan Stanley raised Valeant's price target to $284 and increased estimates based on strong organic growth prospects and additional M&A that can drive further upside. The firm rates shares an Overweight.
07:12 EDTVRXRedHill Biopharma provides update on RHB-106 program
RedHill Biopharma (RDHL) provided an update on its RHB-106 tasteless solid oral formulation bowel preparation development program under the worldwide exclusive license agreement with Salix Pharmaceuticals, recently acquired by Valeant Pharmaceuticals International (VRX). Salix confirmed to RedHill that it continues the development of RHB-106. Salix further clarified to RedHill that the bowel purgative product referenced in Valeant's Q2 financial results presentation1 as a failed toxicology screen is not RedHill's RHB-106. On February 27, 2014, RedHill and Salix entered into an exclusive license agreement under which Salix acquired the worldwide exclusive rights to RedHill's RHB-106 encapsulated formulation for bowel preparation and rights to other purgative developments. Financial terms of the transaction included an upfront payment to RedHill of $7M, and an additional $5M in subsequent milestone payments to RedHill. Salix also agreed to pay RedHill tiered royalties on net sales, ranging from low single digits up to low double digits. RHB-106 is an encapsulated formulation intended for the preparation and cleansing of the gastrointestinal tract prior to the performance of abdominal procedures, including diagnostic tests such as colonoscopies, barium enemas or virtual colonoscopies, as well as surgical interventions, such as laparotomies. RHB-106 is a tasteless solid oral dosage potentially allowing an unobstructed procedure with reduced side effects and improved compliance. It is also intended to prevent patient exposure to the often unappealing taste of current products.
July 24, 2015
07:06 EDTVRXValeant price target raised to $285 from $255 at UBS
Subscribe for More Information
06:51 EDTVRXValeant price target raised to $290 from $250 at JPMorgan
JPMorgan analyst Chris Schott raised his price target for Valeant Pharmaceuticals to $290 citing the company's "very strong" Q2 results. Schott sees further upside to estimates and reiterates an Overweight rating on the stock.
July 23, 2015
12:12 EDTVRXValeant beats RBC as biggest Canadian company by market value, Bloomberg says
Valeant (VRX) has surpassed Royal Bank of Canada (RY) as the largest Canadian company by market value on the Toronto Stock Exchange, Bloomberg reports. Valeant surged 4.5% to a total market value of C$111.3B at 11:21 AM in Toronto, beating the Royal Bank's C$108.3B market value, the report says. Reference Link
06:29 EDTVRXValeant raises FY15 cash EPS view to $11.5-$11.80 from $10.90-$11.20
Subscribe for More Information
06:26 EDTVRXValeant sees Q4 cash EPS $3.98-$4.18, consensus $3.49
Sees Q4 revenue $3.2B-$3.4B, consensus $3.03B.
06:25 EDTVRXValeant sees Q3 cash EPS $2.60-$2.70, consensus $2.86
Sees Q3 revenue $2.6B-$2.8B, consensus $2.74B.
06:24 EDTVRXValeant reports Q2 cash EPS $2.56, consensus $2.46
Subscribe for More Information
06:06 EDTVRXValeant raises FY15 cash EPS to $11.50-$11.80 from $10.90-$11.20
The increased EPS guidance reflects continued business outperformance and approval of IBS-D indication for Xifaxan. Raises FY15 total revenue to $10.7B-$10.4B from $10.4B-$10.6B. Sees FY15 Salix revenue $1.2B. Raises FY15 adjusted cash flow from operations to be greater than $3.2B from greater than $3.1B. Sees FY15 SSS organic growth of greater than 10% for 2H15.
06:05 EDTVRXValeant sees Q4 cash EPS $3.98-$4.18, revenue $3.2B-$3.4B
Subscribe for More Information
06:05 EDTVRXValeant sees Q3 cash EPS $2.60-$2.70, revenue $2.6B-$2.8B
Subscribe for More Information
06:04 EDTVRXValeant reports Q2 GAAP EPS (15c), Q2 cash EPS $2.56
Excluding negative impact of ForEx and Salix, cash EPS would have been $2.73. Reports Q2 total revenue $2.73B vs. $2.04B last year. Reports Q2 Product sales $2.70B vs. $1.99B last year. Reports Q2 SSS organic growth up 19%. Reports Q2 Salix revenue $313M.
July 21, 2015
10:01 EDTVRXOn The Fly: Analyst Initiation Summary
Subscribe for More Information
July 20, 2015
16:15 EDTVRXValeant initiated with a Buy at BTIG
Subscribe for More Information
08:38 EDTVRXAnalyst predicts Zoetis merges with Bayer unit, not Valeant
Zoetis (ZTS) in recent months has been the subject of takeover speculation, possibly for Valeant (VRX), but a Jefferies analyst told investors today in a research note that he views a deal with a unit of healthcare giant Bayer (BAYRY) as "highly likely" for the animal medicine company. BACKGROUND: Bill Ackman of Pershing Square, who owns stakes in both Zoetis and Valeant, said in early May while speaking on CNBC that Zoetis is a "great” business on a standalone basis, but he also spoke of the company's strategic value. Ackman added, however, that he was "not sure" that Valeant was the best acquirer of Zoetis. Subsequently, in late June, The Wall Street Journal reported that Valeant made a preliminary approach regarding a potential deal to buy Zoetis. CNBC's David Faber said the next day, citing his own sources, that Valeant reached out to Zoetis as a courtesy to common shareholder Ackman and was unlikely to pursue an acquisition of the company, though he cautioned then Valeant could change its approach and pursue a deal. BAYER: Jefferies analyst Jeffrey Holford said in a note today that he views a tie-up between Zoetis and Bayer's Animal Health business in 2016 as "highly likely." He sees Mylan's (MYL) acquisition of Abbott's (ABT) non‑U.S. developed markets specialty and branded generics business as a potential proxy for how a transaction could be structured, adding that such a "spinversion" could achieve up to 36% long-term earnings accretion for Zoetis. Holford reiterated a Buy rating on Zoetis with a $60 price target, while downgrading Bayer to Hold, citing valuation following the recent outperformance of its shares. IDEXX: While being discussed as a target, some analysts have also opined on companies that Zoetis could pursue as a buyer. On June 29, Canaccord said that in investor meetings with IDEXX (IDXX) executives declined to comment on Zoetis' potential interest in scaling up its animal health diagnostics business. Canaccord added that it thought Zoetis could make a bid for IDEXX. The firm reiterated its Buy rating and $80 price target on IDEXX shares at that time. PRICE ACTION: Since June 25, the day the Journal first reported on Valeant's preliminary takeover approach to Zoetis, the animal health company's shares have dropped nearly 4%. Zoetis closed down 20c to $47.80 on Friday.
07:33 EDTVRXValeant price target raised to $285 from $275 at Canaccord
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use